Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 900 million dogs on planet earth
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by losingmyshirton Mar 03, 2021 10:30am
106 Views
Post# 32704217

RE:RE:RE:900 million dogs on planet earth

RE:RE:RE:900 million dogs on planet earth
Bigginvestor wrote:
loosing my shirt. U were hateing now you loving the company pick one side will you.!!


I have seen the light and I have found the right path.

After reading the articles about Nitric Oxide for dogs, I am convinced. Garry Southan of Salzman/Claritas is the shining light and he will lead us out of darkness.
No one else on this planet has devoted more time to solving the mystery of dog breath.
Go KLY.

I will not flinch when KLY drops to .04 because I know, in the long run, this new treatment that Kaly is working on, will ultimately benefit all dogs worldwide no matter what breed.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities